Novel Hep C Strategy Aimed at Host Cells | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

99% Cured of Hep C in Abbott's Interferon-Free Regimen

Back to News Homepage
Next

Tying Joint Pain and Hepatitis C Together

Novel Hep C Strategy Aimed at Host Cells

The Editors at Hepatitis Central
October 19, 2012

Print this page

An Israeli company has a drug in development with a unique approach for fighting Hepatitis C – targeting the host cell instead of the virus itself.

A New And Interesting Addition To The Hep C Clinical Pipeline

October 17, 2012

The race towards an interferon-free hepatitis C treatment continues to heat up, with a newcomer to the clinical pipeline – BioLine Rx’s (BLRX) BL-8020. The Israeli company, which in-licensed the drug earlier this year, announced that it had successfully completed the pre-clinical development of the anti Hep C drug, and that a phase I/II is planned to begin in Europe during the first quarter of 2013.

Unlike the vast majority of Hep C drugs under development, BL-8020 is not a protease or polymerase inhibitor. In fact, this drug doesn’t directly target the hepatitis virus at all, but instead, targets the host cell. BL-8020 inhibits a naturally occurring mechanism in the cell termed “autophagy”, which is used by the hepatitis C (and other viruses) for its replication process. This unique mechanism of action provides BioLine’s drug with several advantages:

Continue reading this entire article:
http://seekingalpha.com/article/929921-a-new-and-interesting-addition-to-the-hep-c-clinical-pipeline

1 Comment
Share
Share
Previous

99% Cured of Hep C in Abbott's Interferon-Free Regimen

Back to News Homepage
Next

Tying Joint Pain and Hepatitis C Together

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.